Oncology Articles | Page 2

Pancreatic Ductal Carcinoma: Slow Progress for a Hard-to-Treat Cancer
Pancreatic ductal adenocarcinoma, which is considered incurable, accounts for more than 90% of pancreatic cancer cases.
Fewer than 4% of patients with cancer in the United States participate in clinical trials, the elderly and individuals with clinically relevant comorbidities are strikingly underrepresented in the research portfolio.
The FDA has granted a priority review to the CAR T-cell therapy tisagenlecleucel for adult patients with relapsed/refractory DLBCL who are ineligible for or relapse after autologous stem cell transplant. 
Cabozantinib Improves OS, PFS in Advanced HCC
Treatment with cabozantinib improved median overall survival by 2.2 months compared with placebo for patients with previously treated advanced hepatocellular carcinoma.
Abiraterone Associated With Improved PROs in Metastatic Prostate Cancer
Men with newly diagnosed mCRPC in the global LATITUDE trial reported clinical improvements in pain progression, prostate cancer symptoms, fatigue, functional decline, and overallHR-QOL following treatment with abiraterone acetate plus prednisone.
Frontline Pembrolizumab Combo Improves Survival in Phase III NSCLC Trial
Combining pembrolizumab with chemotherapy in the frontline setting improved survival in patients with nonsquamous non–small cell lung cancer.
FDA Approves Arsenic Trioxide for Promyelocytic Leukemia
The FDA has approved arsenic trioxide (Trisenox) in combination with the all-trans retinoic acid agent tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia with the t(15;17) translocation or PML-RARA gene expression.
Demand Builds for Access to Experimental Drugs
Right-to-try legislation, which allows dying patients to take investigational medications without approval from the FDA.
Molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with significant differences seen in overall survival and disease-free survival between groupings.
Paul A. Bunn, Jr, MD, discusses the IMpower150 study and other immunotherapy combinations in NSCLC.
Publication Bottom Border
Border Publication